Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

EOM Pharmaceutical Holdings Inc (PK) IMUC

Healthcare Biotechnology
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.


PINL:IMUC - Post by User

EOM Pharmaceutical Holdings Inc (PK)
Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • pericles1X
Post by pericles1on Jun 01, 2014 5:57pm
330 Views
Post# 22619337

Good news!

Good news!
I had sold all my shares, but may pick up a new position. They have a subgroup that may be good enough for approval. Since HLA2 is only in about half the patients and Merthylated is also only in less than half we are getting to a smaller percentage. . I don't know what It is but on the negative side for maybe 70% of Glio, patients it will not be an effective treatment. Will certainly have to run a new phase III. Definitely good news but not great, IMHO. but the stock lives. Will wait to see how far it opens up but will not chase it to far tomorrow.
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities